Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

Clinical trial NCT04389840 · TERMINATED

Trial details

NCT number: NCT04389840
Sponsor: Jazz Pharmaceuticals
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Coronavirus Disease 2019 (COVID-19)Acute Lung Injury Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Start date: 2020-07-08
Primary completion: 2021-05-20
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.